← Back to Search

Survivorship and Palliative Care Model for Lung Cancer

Led By Laura A Petrillo, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Receiving targeted therapy
Within 6 months of diagnosis of metastatic NSCLC with oncogenic driver mutation (EGFR, ALK, ROS1, RET)
Screening 3 weeks
Treatment Varies
Follow Up 20 weeks
Awards & highlights
No Placebo-Only Group

Study Summary

This trial is developing a care model to help people with metastatic lung cancer cope with uncertainty and understand their prognosis and treatment goals, so they can live well with cancer.

Who is the study for?
This trial is for adults diagnosed with metastatic Non-small Cell Lung Cancer (NSCLC) within the last 6 months, who are receiving targeted therapy and can communicate in English or Spanish. It's specifically for patients at MGH Cancer Center. Pregnant women, prisoners, those needing urgent palliative care, or individuals with cognitive impairments that prevent informed consent are excluded.Check my eligibility
What is being tested?
The study is testing a new supportive care model called POISE designed for NSCLC patients. POISE involves four sessions with a trained clinician compared to standard care. The focus is on its feasibility, acceptability, and impact on patient distress about their future, cancer management confidence, and understanding of what to expect.See study design
What are the potential side effects?
Since POISE is a supportive care model rather than a medication or medical procedure, it does not have traditional side effects. However, discussing serious illness may cause emotional discomfort or distress.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am currently on targeted therapy for my condition.
My lung cancer was diagnosed within the last 6 months and has a specific mutation.
I can communicate in English or Spanish.
I am 18 years old or older.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~20 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 20 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility of POISE
Secondary outcome measures
Distress related to prognostic uncertainty
Documentation of Goals and Values
+1 more
Other outcome measures
Psychological Distress
Uncertainty tolerance

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: POISEExperimental Treatment1 Intervention
The intervention will be a structured palliative care intervention in which patients will meet with a palliative care clinician who has been trained on a manual with specific topics to be covered in each of the four visits: Three surveys: baseline, 12-week, and 20-week post-enrollment Four 60-minute visits with a trained palliative care clinician Semi-structured exit interview Chart review
Group II: Usual careActive Control1 Intervention
Patients randomized to usual care will receive usual oncology care. They may access standard palliative care as clinically indicated.

Find a Location

Who is running the clinical trial?

American Lung AssociationOTHER
31 Previous Clinical Trials
10,887 Total Patients Enrolled
Massachusetts General HospitalLead Sponsor
2,903 Previous Clinical Trials
13,185,646 Total Patients Enrolled
Laura A Petrillo, MDPrincipal InvestigatorMassachusetts General Hospital
1 Previous Clinical Trials
210 Total Patients Enrolled

Media Library

POISE Clinical Trial Eligibility Overview. Trial Name: NCT04900935 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there open slots available for the current clinical trial?

"Clinicaltrials.gov indicates that this particular medical trial, which was first announced on October 1st 2022, is not presently seeking participants. Nonetheless, there are 2140 other studies currently recruiting patients."

Answered by AI
~60 spots leftby Jan 2027